A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC 681239) and Bendamustine in Patients With Untreated Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Dec 2017
At a glance
- Drugs Bortezomib (Primary) ; Bendamustine; Ofatumumab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 12 Dec 2017 Primary endpoint (Complete response rate) has not been met, according to results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology.
- 12 Jul 2017 Planned primary completion date changed from 30 Jun 2017 to 31 Dec 2017.